The Brookhaven Linac Isotope Producer (BLIP)
Built in 1972, the Brookhaven Linac Isotope Producer facility, or BLIP, at Brookhaven National Laboratory consists of a 30 m beam line and target area that shares protons up to 200 MeV and 165 µA with BNL’s nuclear physics program at the Relativistic Heavy Ion Collider. Protons are directed at specific target materials, enabling the production of a variety of isotopes for distribution to the nuclear medicine and industrial communities for research and commercial purposes. BLIP is also used for R&D of new and improved isotope production capabilities and to perform non-isotope irradiations such as materials research.
Once targets are irradiated in a water-cooled holder, they are raised from the accelerator vault to a hot cell with remote handling. Next, the irradiated targets are appropriately packaged and transported on-site to a dedicated hot cell processing facility that includes eight radiochemistry development labs, nine lead and steel hot cells, and an instrumentation lab for radionuclide and elemental assay.
Production of isotopes in the BLIP is dependent upon the operating cycle of the linear accelerator (Linac). The schedule and duration of Linac operations are determined by the plans and funding of the nuclear physics experiments. Key isotopes commonly in production at BLIP include actinium-225, and copper-67.
More information can be found at the BLIP Homepage.
The LANL Isotope Production Facility (IPF)
Commissioned in 2004, the Isotope Production Facility, or IPF, at Los Alamos National Laboratory routinely produces radioisotopes at beam currents up to 275 µA using the 100 MeV proton beam generated at the front end of the Los Alamos Neutron Science Center (LANSCE) accelerator. Resulting high-purity, high-specific-activity isotopes— including actinium-225, sodium-22, and arsenic-73—are utilized across the fields of medicine, fundamental nuclear physics, national security, environmental science, and industrial applications.
The IPF’s water-cooled target holder contains space for three targets, allowing for simultaneous proton-based production in three different energy ranges, as well as the availability of activation of small targets by the high energy secondary neutron flux. Targets are processed at the Hot Cell Facility in the nearby Radiochemistry Complex. This complex is equipped with 13 hot cells, as well as radiological and analytical laboratories and packaging operations. The Hot Cell Facility is where chemical processing occurs to isolate the desired isotope products suitable for use by customers. The IPF and Hot Cell Facility are also used to perform research to explore production and separation of novel radionuclides, including the collection of production-related nuclear data.
More information can be found at the IPF Homepage.
Argonne's Low-Energy Accelerator Facility (LEAF)
The Low-Energy Accelerator Facility, or LEAF, at Argonne National Laboratory combines an electron linear accelerator to enable radioisotope production with a Van de Graaff (VDG) electron accelerator to study radiation effects. The Argonne Radioisotope Research and Production Program (R2P2) performs a wide range of radioisotope separation, purification, and targetry method development and uses the LEAF for radioisotope production (including theranostics copper-67 and scandium-47), radiation testing and material response to received dose, and material activation studies. Since its construction in 1969, the LEAF has undergone significant improvements to boost the beam power and energy, now operating at energy up to 50 MeV and beam power up to 25 kW.
The LEAF’s Linac component can deliver continuous or pulsed beams with energies up to 50 MeV and average power exceeding 20 kW at energies relevant to radioisotope production. It is equipped with multiple target station locations that facilitate remote operations and post-run target transfer. Its counterpart, the low-energy (3 MeV) VDG electron accelerator, can deliver high levels of electron/photon dose rates (in pulsed or continuous mode) to critical components to test for radiation hardness and stability while avoiding activation and handling hazards of the irradiated targets. The R2P2 utilizes Argonne's hot cells, radiochemical laboratories, and the Analytical Chemistry Laboratory to aid in separations, processing, and purity analysis activities.
The University of Washington Medical Cyclotron Facility
In 2016, research staff at the University of Washington’s (UW's) Medical Cyclotron Facility began routinely producing radioisotopes for the DOE IP, primarily the alpha particle-emitting astatine-211, used for cancer treatment research. Its short half-life, combined with a lack of cyclotrons capable of producing high-intensity alpha particle beams, has limited the global availability of astatine-211 in the past, and UW’s unique facility helps to alleviate this demand.
The facility is equipped with a Scanditronix MC50 compact cyclotron that is a fully tunable (with respect to beam energy and current) multi-particle instrument capable of accelerating proton, deuteron, helium-3, and alpha particle beams. Conditions for astatine-211 production at the Medical Cyclotron Facility include a 29 MeV alpha beam with 50 of beam current. The facility also contains two target stations inside the accelerator vault for radionuclide research.
More information can be found at the UW Medical Cyclotron Facility Homepage.